Supportive care treatments for toxicities of anti-egfr and other targeted agents

Area of Science:

• Oncology
• Pharmacology

Background:

• Targeting the epidermal growth factor receptor (EGFR) pathway is standard in lung carcinoma treatment.
• Approvals for targeted therapies are expanding, increasing their clinical use.
• EGFR tyrosine kinase inhibitors (TKIs) like gefitinib and erlotinib are established treatments for non-small-cell lung carcinoma (NSCLC) with EGFR mutations.

Purpose of the Study:

• To review the role of EGFR pathway inhibitors in lung cancer.
• To discuss the unique side-effect profiles of these targeted agents.
• To explore emerging targets like ALK fusion mutations and associated therapies.

Main Methods:

• Literature review of EGFR inhibitors in lung cancer treatment.
• Analysis of side-effect profiles and management strategies for TKIs.
• Discussion of current and investigational targeted therapies.

Main Results:

• Gefitinib is approved for first-line advanced NSCLC with EGFR mutations; erlotinib is approved for second- and third-line settings.
• Common side effects of EGFR TKIs include rash and diarrhea, with established management principles.
• ALK fusion mutations are recognized as drivers, with crizotinib (a TKI) awaiting approval.

Conclusions:

• EGFR pathway targeting is a cornerstone of modern lung cancer therapy.
• Effective management of TKI-related side effects is essential for patient outcomes.
• Further research into novel targets like ALK is expanding treatment options.